Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA.
Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA.
Med Clin North Am. 2024 Sep;108(5):829-842. doi: 10.1016/j.mcna.2024.02.004. Epub 2024 Apr 8.
Seven of the 11 newer medications recently or soon to be approved to treat rheumatologic diseases discussed in this article are biologic agents and reflect the current ability of science to target specific components of the immune system. The other agents are molecules that are directed against specific immune pathway targets as well. All have shown superiority to placebo and in some cases have been compared to currently accepted therapies. Safety issues are generally centered around infections due to the immune-interrupting nature of these therapies.
本文讨论了最近或即将获得批准用于治疗风湿性疾病的 11 种新药中的 7 种是生物制剂，这反映了科学靶向免疫系统特定成分的当前能力。其他药物也是针对特定免疫途径靶点的分子。所有这些药物都显示出优于安慰剂的效果，在某些情况下还与目前可接受的治疗方法进行了比较。安全性问题通常集中在由于这些治疗方法具有免疫抑制性质而导致的感染上。
